The use of Soliris (eculizumab) is changing the natural course of atypical hemolytic uremic syndrome (aHUS) in Latin…
Articles by Margarida Maia, PhD
Adults with atypical hemolytic uremic syndrome (aHUS) who switched from Soliris (eculizumab) to long-acting Ultomiris (ravulizumab) in…
The U.S. Food and Drug Administration (FDA) has approved Bkemv (eculizumab-aeeb), the first interchangeable biosimilar to Soliris (eculizumab), to treat…
In a young girl, thrombotic microangiopathy — a group of disorders, including atypical hemolytic uremic syndrome (aHUS), that are…
A team of five experts from across Spain got together to reach a consensus on a set of recommendations for…
A rare mutation in the CFHR5 gene may have led to the excessive activation of the immune complement system, triggering…
Alexion, AstraZeneca Rare Disease signed off on a letter of intent in Canada that brings Ultomiris (ravulizumab) —…
Getting vaccinated against COVID-19 may protect people with atypical hemolytic uremic syndrome (aHUS) from the infection’s severe complications, without raising…
Plasma exchange combined with rituximab, an immunosuppressant, might prevent atypical hemolytic uremic syndrome (aHUS) from coming back after a…
Disease-causing variants in complement genes appear to be uncommon in children with atypical hemolytic uremic syndrome (aHUS) caused by autoantibodies…